Tissue proteomics outlines AGR2 AND LOX5 as markers for biochemical recurrence of prostate cancer
Metrics: PDF 1019 views | HTML 1622 views | ?
Giovanny Rodríguez-Blanco1,*, Lona Zeneyedpour1,*, Diederick Duijvesz2,*, A. Marije Hoogland3, Esther I. Verhoef3, Charlotte F. Kweldam3, Peter C. Burgers1, Peter Sillevis Smitt1, Chris H. Bangma2, Guido Jenster2, Geert J.L.H. van Leenders3, Lennard J.M. Dekker1 and Theo M. Luider1
1Department of Neurology, Erasmus Medical Centre, Rotterdam, The Netherlands
2Department of Urology, Erasmus Medical Centre, Rotterdam, The Netherlands
3Department of Pathology, Erasmus Medical Centre, Rotterdam, The Netherlands
*These authors have contributed equally to this work
Theo M. Luider, email: email@example.com
Keywords: prostate cancer; mass spectrometry; arachidonic acid
Received: August 13, 2018 Accepted: October 21, 2018 Published: November 23, 2018
Although many patients are cured from prostate cancer (PCa) by surgery only, there are still patients who will experience rising prostate-specific antigen (PSA) levels after surgery, a condition known as biochemical recurrence (BCR). Novel protein prognostic markers in PCa tissue might enable finding better treatment for those patients experiencing BCR with a high chance of metastasis. In this study, we aimed to identify altered proteins in prostate cancer tissue, and to evaluate their potential role as prognostic markers. We used two proteomics strategies to analyse 34 prostate tumours (PCa) and 33 normal adjacent prostate (NAP) tissues. An independent cohort of 481 samples was used to evaluate the expression of three proteins: AGR2, FASN and LOX5 as prognostic markers of the disease. Tissue microarray immunohistochemical staining indicated that a low percentage of positive tumour cells for AGR2 (HR (95% CI) = 0.61 (0.43-0.93)), and a low percentage of positive tumour cells for LOX5 expression (HR (95% CI) = 2.53 (1.23-5.22)) are predictors of BCR after RP. In contrast, FASN expression had no prognostic value for PCa.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.